Oxford Immunotec Global (OXFD) Downgraded by BidaskClub

BidaskClub downgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a sell rating in a research note issued to investors on Wednesday.

Other equities research analysts have also issued research reports about the stock. Piper Jaffray Companies restated an overweight rating on shares of Oxford Immunotec Global in a report on Sunday, November 11th. ValuEngine lowered shares of Oxford Immunotec Global from a strong-buy rating to a buy rating in a report on Saturday, December 1st. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $16.67.

Shares of OXFD traded up $0.05 on Wednesday, reaching $15.06. The company’s stock had a trading volume of 6,518 shares, compared to its average volume of 107,356. Oxford Immunotec Global has a twelve month low of $10.00 and a twelve month high of $19.19. The firm has a market capitalization of $395.68 million, a PE ratio of -11.07 and a beta of -0.10.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its earnings results on Friday, November 9th. The company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. The business had revenue of $16.10 million during the quarter, compared to analyst estimates of $33.60 million. During the same quarter in the prior year, the company earned ($0.70) EPS. The company’s revenue was up 7.3% on a year-over-year basis. Sell-side analysts predict that Oxford Immunotec Global will post -1.09 earnings per share for the current fiscal year.

In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 20,000 shares of the company’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $16.71, for a total value of $334,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $15.50, for a total transaction of $46,500.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at $139,500. The disclosure for this sale can be found here. Insiders sold a total of 149,100 shares of company stock valued at $2,564,662 over the last ninety days. 6.61% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the business. Bank of Montreal Can bought a new position in shares of Oxford Immunotec Global during the 2nd quarter valued at approximately $132,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Oxford Immunotec Global during the 2nd quarter valued at approximately $333,000. Wasatch Advisors Inc. grew its position in shares of Oxford Immunotec Global by 18.6% during the 2nd quarter. Wasatch Advisors Inc. now owns 883,761 shares of the company’s stock valued at $11,392,000 after acquiring an additional 138,571 shares during the period. C WorldWide Group Holding A S grew its position in shares of Oxford Immunotec Global by 25.2% during the 2nd quarter. C WorldWide Group Holding A S now owns 164,073 shares of the company’s stock valued at $2,115,000 after acquiring an additional 33,059 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Oxford Immunotec Global by 45.8% during the 2nd quarter. Rhumbline Advisers now owns 32,861 shares of the company’s stock valued at $424,000 after acquiring an additional 10,320 shares during the period. 90.94% of the stock is owned by institutional investors and hedge funds.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Featured Story: What are the risks of holding treasury bonds?

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit